Brought to you by 
Eisai gets cancer candidate rights from SymBio
15 Dec 2020
Executive Summary
Japanese drug start-up SymBio Pharmaceuticals has granted Eisai (neurology, cancer, and immune disorder therapeutics) co-development and exclusive commercialization rights in Japan to its bendamustine (SyB L0501) oncology candidate.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Eisai gets cancer candidate rights from SymBio
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice